Dova Pharmaceuticals set terms of its initial public offering, which the developer of drug candidates for diseases treated by specialist physicians expects to raise up to $69.1 million. In a filing with the Securities and Exchange Commission Monday, the company said it was offering 4.06 million shares for sale in the IPO, which it expects to price between $15 and $17 a share. If the options granted to the underwriters to cover overallotments are exercised, the company could sell 4.7 million shares to raise $79.4 million. The company has applied to list the stock on the Nasdaq Global Market under the ticker symbol "DOVA." J.P. Morgan, Jefferies and Leerink Partners are the lead underwriters.
Continue Reading Below
Copyright © 2017 MarketWatch, Inc.